Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
verfasst von:
Francine Foss, Steven Horwitz, Barbara Pro, H. Miles Prince, Lubomir Sokol, Barbara Balser, Julie Wolfson, Bertrand Coiffier
The original article [1] contains an error whereby Fig. 2a & b are mistakenly interchanged and contain incorrect colour-coding.
Fig. 2:
Survival based on clinical IRC assessment by best response to romidepsin (n = 130). Progression-free survival (a) and overall survival (b). Patients with insufficient efficacy data to determine response due to early termination (NE; n = 29) were included as nonresponders. NE not evaluable
×
The correct versions of Fig. 2a & b are thus displayed below.
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
verfasst von
Francine Foss Steven Horwitz Barbara Pro H. Miles Prince Lubomir Sokol Barbara Balser Julie Wolfson Bertrand Coiffier
